Búsqueda | Portal de Búsqueda de la BVS España

1.

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.

Callaghan, Michael U; Negrier, Claude; Paz-Priel, Ido; Chang, Tiffany; Chebon, Sammy; Lehle, Michaela; Mahlangu, Johnny; Young, Guy; Kruse-Jarres, Rebecca; Mancuso, Maria Elisa; Niggli, Markus; Howard, Monet; Bienz, Nives Selak; Shima, Midori; Jiménez-Yuste, Victor; Schmitt, Christophe; Asikanius, Elina; Levy, Gallia G; Pipe, Steven W; Oldenburg, Johannes.

Blood; 137(16): 2231-2242, 2021 04 22.

Artículo en Inglés | MEDLINE | ID: mdl-33512413

2.

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.

Kiialainen, Anna; Niggli, Markus; Kempton, Christine L; Castaman, Giancarlo; Chang, Tiffany; Paz-Priel, Ido; Adamkewicz, Joanne I; Levy, Gallia G.

Haemophilia; 28(6): 1033-1043, 2022 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-35905294

3.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Mahlangu, Johnny; Oldenburg, Johannes; Paz-Priel, Ido; Negrier, Claude; Niggli, Markus; Mancuso, M Elisa; Schmitt, Christophe; Jiménez-Yuste, Victor; Kempton, Christine; Dhalluin, Christophe; Callaghan, Michael U; Bujan, Willem; Shima, Midori; Adamkewicz, Joanne I; Asikanius, Elina; Levy, Gallia G; Kruse-Jarres, Rebecca.

N Engl J Med; 379(9): 811-822, 2018 08 30.

Artículo en Inglés | MEDLINE | ID: mdl-30157389

4.

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

Young, Guy; Liesner, Ri; Chang, Tiffany; Sidonio, Robert; Oldenburg, Johannes; Jiménez-Yuste, Victor; Mahlangu, Johnny; Kruse-Jarres, Rebecca; Wang, Michael; Uguen, Marianne; Doral, Michelle Y; Wright, Lilyan Y; Schmitt, Christophe; Levy, Gallia G; Shima, Midori; Mancuso, Maria Elisa.

Blood; 134(24): 2127-2138, 2019 12 12.

Artículo en Inglés | MEDLINE | ID: mdl-31697801

5.

The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.

Skinner, Mark W; Négrier, Claude; Paz-Priel, Ido; Chebon, Sammy; Jiménez-Yuste, Victor; Callaghan, Michael U; Lehle, Michaela; Niggli, Markus; Mahlangu, Johnny; Shapiro, Amy; Shima, Midori; Campinha-Bacote, Avrita; Levy, Gallia G; Oldenburg, Johannes; von Mackensen, Sylvia; Pipe, Steven W.

Haemophilia; 27(5): 854-865, 2021 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-34171159

6.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Oldenburg, Johannes; Mahlangu, Johnny N; Kim, Benjamin; Schmitt, Christophe; Callaghan, Michael U; Young, Guy; Santagostino, Elena; Kruse-Jarres, Rebecca; Negrier, Claude; Kessler, Craig; Valente, Nancy; Asikanius, Elina; Levy, Gallia G; Windyga, Jerzy; Shima, Midori.

N Engl J Med; 377(9): 809-818, 2017 08 31.

Artículo en Inglés | MEDLINE | ID: mdl-28691557

7.

Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.

Oldenburg, Johannes; Shima, Midori; Kruse-Jarres, Rebecca; Santagostino, Elena; Mahlangu, Johnny; Lehle, Michaela; Selak Bienz, Nives; Chebon, Sammy; Asikanius, Elina; Trask, Peter; Mancuso, Maria Elisa; Jiménez-Yuste, Victor; von Mackensen, Sylvia; Levy, Gallia G.

Pediatr Blood Cancer; 67(10): e28474, 2020 10.

Artículo en Inglés | MEDLINE | ID: mdl-32776489

8.

Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Mahlangu, Johnny; Oldenburg, Johannes; Callaghan, Michael U; Shima, Midori; Mancuso, Maria Elisa; Trask, Peter; Recht, Michael; Garcia, Claudia; Yang, Renchi; Lehle, Michaela; Macharia, Harrison; Asikanius, Elina; Levy, Gallia G; Kruse-Jarres, Rebecca; von Mackensen, Sylvia.

Haemophilia; 25(3): 382-391, 2019 May.

Artículo en Inglés | MEDLINE | ID: mdl-31016855

9.

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.

Mahlangu, Johnny; Oldenburg, Johannes; Callaghan, Michael U; Shima, Midori; Santagostino, Elena; Moore, Maggie; Recht, Michael; Garcia, Claudia; Yang, Renchi; Lehle, Michaela; Macharia, Harrison; Asikanius, Elina; Levy, Gallia G; Kruse-Jarres, Rebecca.

Haemophilia; 24(6): 921-929, 2018 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-30295389

10.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Oldenburg, Johannes; Levy, Gallia G.

N Engl J Med; 377(22): 2194-2195, 2017 11 30.

Artículo en Inglés | MEDLINE | ID: mdl-29171814

11.

A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A.

Yoneyama, Koichiro; Schmitt, Christophe; Chang, Tiffany; Dhalluin, Christophe; Nagami, Sayaka; Petry, Claire; Levy, Gallia G.

J Clin Pharmacol; 62(2): 232-244, 2022 02.

Artículo en Inglés | MEDLINE | ID: mdl-34545950

12.

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.

Callaghan, Michael U; Asikanius, Elina; Lehle, Michaela; Oldenburg, Johannes; Mahlangu, Johnny; Uguen, Marianne; Chebon, Sammy; Kruse-Jarres, Rebecca; Jiménez-Yuste, Víctor; Shima, Midori; Trask, Peter; Kempton, Christine L; Kessler, Craig M; Levy, Gallia G; Peyvandi, Flora.

Res Pract Thromb Haemost; 6(6): e12782, 2022 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-36171959

13.

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.

Schmitt, Christophe; Adamkewicz, Joanne I; Xu, Jin; Petry, Claire; Catalani, Olivier; Young, Guy; Negrier, Claude; Callaghan, Michael U; Levy, Gallia G.

Thromb Haemost; 121(3): 351-360, 2021 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-33086400

14.

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.

Lu, Genmin; Conley, Pamela B; Leeds, Janet M; Karbarz, Mark J; Levy, Gallia G; Mathur, Vandana S; Castillo, Janice; Crowther, Mark; Curnutte, John T.

Blood Adv; 4(4): 728-739, 2020 02 25.

Artículo en Inglés | MEDLINE | ID: mdl-32092140

15.

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.

Levy, Gallia G; Asikanius, Elina; Kuebler, Peter; Benchikh El Fegoun, Soraya; Esbjerg, Sille; Seremetis, Stephanie.

J Thromb Haemost; 17(9): 1470-1477, 2019 09.

Artículo en Inglés | MEDLINE | ID: mdl-31124272

16.

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.

Pipe, Steven W; Shima, Midori; Lehle, Michaela; Shapiro, Amy; Chebon, Sammy; Fukutake, Katsuyuki; Key, Nigel S; Portron, Agnès; Schmitt, Christophe; Podolak-Dawidziak, Maria; Selak Bienz, Nives; Hermans, Cedric; Campinha-Bacote, Avrita; Kiialainen, Anna; Peerlinck, Kathelijne; Levy, Gallia G; Jiménez-Yuste, Victor.

Lancet Haematol; 6(6): e295-e305, 2019 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-31003963

17.

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

Yoneyama, Koichiro; Schmitt, Christophe; Kotani, Naoki; Levy, Gallia G; Kasai, Ryu; Iida, Satofumi; Shima, Midori; Kawanishi, Takehiko.

Clin Pharmacokinet; 57(9): 1123-1134, 2018 09.

Artículo en Inglés | MEDLINE | ID: mdl-29214439

18.

The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder allele.

Johnsen, Jill M; Levy, Gallia G; Westrick, Randal J; Tucker, Priscilla K; Ginsburg, David.

Mamm Genome; 19(1): 32-40, 2008 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-18188647

19.

Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene.

Lemmerhirt, Heidi L; Shavit, Jordan A; Levy, Gallia G; Cole, Suzanne M; Long, Jeffrey C; Ginsburg, David.

Blood; 108(9): 3061-7, 2006 Nov 01.

Artículo en Inglés | MEDLINE | ID: mdl-16873672

20.

ADAMTS13 turns 3.

Levy, Gallia G; Motto, David G; Ginsburg, David.

Blood; 106(1): 11-7, 2005 Jul 01.

Artículo en Inglés | MEDLINE | ID: mdl-15774620

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.

Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A.

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.

Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.

A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.

The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder allele.

Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene.

ADAMTS13 turns 3.